Comparative Pharmacology
Head-to-head clinical analysis: IOBENGUANE I 123 versus NEPHROSCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOBENGUANE I 123 versus NEPHROSCAN.
IOBENGUANE I-123 vs NEPHROSCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iobenguane I-123 is a radiopharmaceutical analog of norepinephrine that is taken up by adrenergic neurons and neuroendocrine tumors via the norepinephrine transporter (NET). It localizes in tissues rich in sympathetic innervation and tumors expressing NET, enabling scintigraphic imaging.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
Intravenous administration of 5 mCi (185 MBq) as a single dose for imaging.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours; clinically relevant for imaging timing (optimal scanning at 24 hours post-injection)
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 40-60% as unchanged iobenguane within 24 hours; biliary/fecal: minimal (<5%)
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical